Free Trial

AxoGen (AXGN) Competitors

AxoGen logo
$10.98 +0.05 (+0.41%)
As of 10:19 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

AXGN vs. NVCR, WRBY, SSII, CNMD, LMAT, TNDM, EYE, CDRE, LQDA, and AORT

Should you be buying AxoGen stock or one of its competitors? The main competitors of AxoGen include NovoCure (NVCR), Warby Parker (WRBY), SS Innovations International (SSII), CONMED (CNMD), LeMaitre Vascular (LMAT), Tandem Diabetes Care (TNDM), National Vision (EYE), Cadre (CDRE), Liquidia (LQDA), and Artivion (AORT). These companies are all part of the "medical equipment" industry.

AxoGen vs.

NovoCure (NASDAQ:NVCR) and AxoGen (NASDAQ:AXGN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, community ranking, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

NovoCure received 20 more outperform votes than AxoGen when rated by MarketBeat users. However, 72.93% of users gave AxoGen an outperform vote while only 62.98% of users gave NovoCure an outperform vote.

CompanyUnderperformOutperform
NovoCureOutperform Votes
478
62.98%
Underperform Votes
281
37.02%
AxoGenOutperform Votes
458
72.93%
Underperform Votes
170
27.07%

NovoCure has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, AxoGen has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500.

84.6% of NovoCure shares are held by institutional investors. Comparatively, 80.3% of AxoGen shares are held by institutional investors. 6.3% of NovoCure shares are held by insiders. Comparatively, 2.8% of AxoGen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

AxoGen has a net margin of -7.91% compared to NovoCure's net margin of -25.93%. AxoGen's return on equity of -14.91% beat NovoCure's return on equity.

Company Net Margins Return on Equity Return on Assets
NovoCure-25.93% -41.48% -12.74%
AxoGen -7.91%-14.91%-7.49%

AxoGen has lower revenue, but higher earnings than NovoCure. AxoGen is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NovoCure$621.71M3.24-$207.04M-$1.51-11.98
AxoGen$194.52M2.57-$21.72M-$0.15-73.23

NovoCure currently has a consensus target price of $32.83, suggesting a potential upside of 81.54%. AxoGen has a consensus target price of $22.20, suggesting a potential upside of 102.09%. Given AxoGen's stronger consensus rating and higher probable upside, analysts plainly believe AxoGen is more favorable than NovoCure.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NovoCure
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.67
AxoGen
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, NovoCure had 4 more articles in the media than AxoGen. MarketBeat recorded 8 mentions for NovoCure and 4 mentions for AxoGen. NovoCure's average media sentiment score of 1.36 beat AxoGen's score of 0.67 indicating that NovoCure is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NovoCure
7 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
AxoGen
4 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

AxoGen beats NovoCure on 10 of the 18 factors compared between the two stocks.

Get AxoGen News Delivered to You Automatically

Sign up to receive the latest news and ratings for AXGN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AXGN vs. The Competition

MetricAxoGenElectromedical equipment IndustryMedical SectorNASDAQ Exchange
Market Cap$504.90M$3.13B$5.31B$8.28B
Dividend YieldN/A1.72%5.20%4.10%
P/E Ratio-34.6416.9526.7319.58
Price / Sales2.5795.82387.44119.65
Price / CashN/A44.0938.2534.62
Price / Book4.953.716.744.47
Net Income-$21.72M$94.03M$3.23B$248.22M
7 Day Performance-7.14%-0.27%-0.05%-1.32%
1 Month Performance-29.67%18.50%8.51%10.73%
1 Year Performance79.79%-9.88%18.25%8.40%

AxoGen Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AXGN
AxoGen
3.2587 of 5 stars
$10.99
+0.4%
$22.20
+102.1%
+76.5%$504.90M$194.52M-34.64450
NVCR
NovoCure
3.5988 of 5 stars
$18.57
+6.8%
$32.83
+76.8%
-23.6%$2.07B$621.71M-13.261,320Positive News
Gap Up
WRBY
Warby Parker
3.083 of 5 stars
$18.88
+19.9%
$22.21
+17.6%
+19.6%$1.97B$795.09M-69.943,030Analyst Forecast
Analyst Revision
High Trading Volume
SSII
SS Innovations International
N/A$10.15
+0.6%
N/AN/A$1.96B$20.65M0.004High Trading Volume
CNMD
CONMED
4.5086 of 5 stars
$60.75
+6.4%
$62.20
+2.4%
-25.1%$1.88B$1.32B14.334,100Positive News
Dividend Announcement
LMAT
LeMaitre Vascular
2.588 of 5 stars
$82.46
+2.7%
$98.14
+19.0%
-1.1%$1.86B$226.26M45.06490Insider Trade
TNDM
Tandem Diabetes Care
4.4326 of 5 stars
$23.45
+2.0%
$39.81
+69.8%
-59.8%$1.56B$982.95M-12.152,600Positive News
Analyst Forecast
Gap Up
EYE
National Vision
2.7575 of 5 stars
$18.76
+9.3%
$17.57
-6.3%
+22.0%$1.48B$1.82B-93.8014,000Positive News
High Trading Volume
CDRE
Cadre
3.6121 of 5 stars
$35.75
+1.0%
$37.00
+3.5%
+4.1%$1.45B$559.81M43.072,240
LQDA
Liquidia
3.4781 of 5 stars
$15.75
+3.2%
$27.13
+72.2%
+18.5%$1.35B$14.00M-9.6650Analyst Forecast
Gap Up
AORT
Artivion
2.3499 of 5 stars
$28.79
-0.4%
$31.40
+9.1%
+19.4%$1.23B$390.08M-1,439.351,300Insider Trade

Related Companies and Tools


This page (NASDAQ:AXGN) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners